2022
DOI: 10.1016/j.ejca.2022.01.012
|View full text |Cite
|
Sign up to set email alerts
|

Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
41
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(42 citation statements)
references
References 49 publications
1
41
0
Order By: Relevance
“…CEA is a cell surface glycoprotein expressed by normal mucosal cells, but is overexpressed in cancers. The CEA level was useful for predicting CRLM patient outcomes [ 10 , 20 , 21 ]. We also found that CEA-positive young-onset CRLM patients had a worse prognosis than CEA-negative patients.…”
Section: Discussionmentioning
confidence: 99%
“…CEA is a cell surface glycoprotein expressed by normal mucosal cells, but is overexpressed in cancers. The CEA level was useful for predicting CRLM patient outcomes [ 10 , 20 , 21 ]. We also found that CEA-positive young-onset CRLM patients had a worse prognosis than CEA-negative patients.…”
Section: Discussionmentioning
confidence: 99%
“…The CRS is included for reference as most prognostic models used the CRS to compare the performance of their models [11]. Twelve prognostic models incorporating RAS mutation status as a predictor of outcomes after resection of CRLM have been published since 2017 [19][20][21][22][23][24][25][26][27][28][29][30]. Ten models were developed and validated by including patients from 2000 onwards, which parallels key developments in systemic chemotherapy such as the introduction of irinotecan and oxaliplatin as components of cytotoxic combination therapy and the use of biological agents such as bevacizumab, cetuximab, and panitumumab [4].…”
Section: Prognostic Models Incorporating Ras Mutation Statusmentioning
confidence: 99%
“…Ten models were developed and validated by including patients from 2000 onwards, which parallels key developments in systemic chemotherapy such as the introduction of irinotecan and oxaliplatin as components of cytotoxic combination therapy and the use of biological agents such as bevacizumab, cetuximab, and panitumumab [4]. Although the most recent, largest, and longest longitudinal study to date by Buisman et al, 2020 included patients from a long inclusion period (1992-2019) to estimate 10-year overall survival, the cohort largely reflects contemporary patient selection and treatment as most patients (82.0%) underwent resection after 2000 [30]. Nine studies included a validation cohort [21][22][23][25][26][27][28][29][30].…”
Section: Prognostic Models Incorporating Ras Mutation Statusmentioning
confidence: 99%
See 2 more Smart Citations